HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US VMS Industry Makes Lame Duck Session List, Checks It Twice For MPL Language

Executive Summary

AHPA urges chairs and ranking members of Senate HELP and House Energy and Commerce committees not to pass mandatory product listing legislation or make other changes to FDA regulation of industry before the 117th Congress ends. NPA board members lobby lawmakers about the topic.

You may also be interested in...



US FDA Supplement Facility Inspection Numbers Back To Typical Along With GMP Problems Found

Supplement facility GMP inspections by FDA in 2022 along with the frequency of form 483s sent to firms following inspections return to roughly pre-pandemic annual numbers after dipping during 2020 and 2021.

Empowered By Evidence Debuts Lists Of Natural Health Ingredients Meeting Its Standards

Global nonprofit supporting evidence-based product development in natural health sector and American Botanical Council announce database intended to help consumers, researchers and health care professionals make natural product choices based on specific scientific and clinical evidence.

Absent Mandatory Listing, US FDA Acknowledges Its Supplement Directory Isn’t Comprehensive

Two weeks after Commissioner Califf notes he supports mandatory listing of supplements and two months after previous session of Congress ended without imposing requirement, agency is doing what it can to publish information about ingredients in supplements sold in the country.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel